Biotech - Rare Diseases
•207 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (207)
| Company | Market Cap | Price |
|---|---|---|
|
SNGX
Soligenix, Inc.
BD (Behçet's Disease) and other rare-disease programs classify Soligenix under Biotech - Rare Diseases.
|
$6.04M |
$1.41
+5.22%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
FDA Orphan Drug Designation for brittle Type 1 Diabetes indicates a rare-disease focus.
|
$5.16M |
$2.02
+6.32%
|
|
KALA
KALA BIO, Inc.
PCED is a rare disease with potential expansion to LSCD and Sjogren's, aligning with Biotech - Rare Diseases.
|
$4.74M |
$0.67
+10.80%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
ALS is a rare neurodegenerative disease, aligning with the Rare Diseases biotech segment and supporting NurOwn's positioning as a therapy for a rare condition.
|
$3.82M |
$0.59
|
|
JAGX
Jaguar Health, Inc.
The company targets rare intestinal diseases (MVID, SBS-IF) with crofelemer programs, fitting the Rare Diseases biotech segment.
|
$2.54M |
$1.18
+3.98%
|
|
NLSP
NLS Pharmaceutics AG
Historically focused on rare CNS disorders, aligning NLSP with Rare Diseases biotechnologies.
|
$745651 |
$0.79
-67.48%
|
|
EMMA
Emmaus Life Sciences, Inc.
The company operates in the rare diseases therapeutic area, centered on Endari for sickle cell disease.
|
$14040 |
$0.01
|
Showing page 3 of 3 (207 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
